- recruitingPHASE1
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
This study is testing a new drug, AJ1-11095, for people with myelofibrosis whose current JAK2 inhibitor treatment is no longer working well. We want to see if it's safe and how it affects the condition.
United States · France · Italy - recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
This study is for people already taking a medicine called bomedemstat for certain blood cancers like thrombocythemia or myelofibrosis. It aims to gather more information over a longer time about how safe and effective bomedemstat is for those who are already benefiting from it.
United States · Australia · Hong Kong - active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
United States · Argentina · Australia - active not recruitingPHASE2
Extended Access of Momelotinib in Adults With Myelofibrosis
This study offers ongoing access to a medication called momelotinib for adults with myelofibrosis. It checks how safe the medicine is long-term and tracks its effects on survival for those already taking part in specific earlier studies and benefiting from the treatment.
United States · Australia · Austria - active not recruitingPHASE3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study looks at a new drug, pacritinib, for people with myelofibrosis and very low platelet counts. It compares pacritinib to other standard treatments decided by your doctor, to see if it can help improve symptoms.
United States · Australia · Belarus - recruitingPHASE3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This study looks at adding a new medicine, navtemadlin, to an existing treatment, ruxolitinib, for people with myelofibrosis. It aims to see if this combination works better for those whose myelofibrosis isn't fully controlled by ruxolitinib alone.
United States · Australia · Austria - recruitingPHASE2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
This study looks at a new combination treatment, momelotinib and luspatercept, for people with myelofibrosis who need regular blood transfusions. It hopes to see if this combination is safe and effective for patients, whether or not they've had previous myelofibrosis treatments.
United States · Canada · France - recruitingPHASE1, PHASE2
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
This study is looking into a new drug, TL-895, for myelofibrosis, a bone marrow disorder. It’s for people who haven't tried a common treatment called ruxolitinib yet, or those who aren't getting enough benefit from ruxolitinib alone.
United States · France · Germany - active not recruitingPHASE4
CINC424A2X01B Rollover Protocol
This study is for patients already taking ruxolitinib, or ruxolitinib with panobinostat, in a previous trial, and who are still benefiting. It lets them continue their treatment and helps researchers learn more about the long-term safety of these medications.
Australia · Belgium · Bulgaria - recruiting
Research Platform Myelofibrosis and Anemia
This study in Germany looks at how people with myelofibrosis and anaemia are treated in real life. It collects information about their health, treatments, and how they feel over time to understand common treatment patterns and changes in their care.
Germany - active not recruitingPHASE3
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
This study is testing a new medicine called pelabresib alongside an existing treatment (ruxolitinib) for adults with myelofibrosis who haven't tried similar drugs before. It aims to see if this combination works better than ruxolitinib alone to help manage symptoms and spleen size.
United States · Australia · Austria